APJ Receptor Agonist 4 is a potent, orally active apelinreceptor (APJ) agonist, demonstrating an EC50 of 0.06 nM and a Ki of 0.07 nM. It exhibits excellent pharmacokinetic profiles in rodent heart failure (HF) models and has shown an acceptable safety profile in preclinical toxicology studies. This compound effectively improves cardiac function, making it valuable for research into HF disease.
APJ receptor agonist 1, a potent biphenyl acid derivative, acts as an agonist (EC50 of 0.093 nM and 0.12 nM for human and rat APJ receptors, respectively) for the APJ receptor (APJ-R). It exhibits significant in vitro potency towards apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 holds promise for heart failure research.
Apelin-12 is a highly potent C-terminal fragment of a polypeptide that exhibits a strong affinity towards the orphan receptor APJ. It plays a role in maintaining body fluid balance and regulating feeding control in the central nervous system. Additionally, Apelin-12 functions as an inhibitor of HIV-1 entry through the APJ receptor and demonstrates neuroprotective properties.
ML233 is a potent non-peptide apelinreceptor agonist (EC50 = 3.7 μM) that exhibits more than 21-fold selectivity over the closely related angiotensin 1 receptor (AT1) (>79 μM) [1].